AI Visibility Scorecard
Breast Cancer Recurrence, Early Stage 1, 2, Breast Cancer Test, India
oncostem.com · Healthcare
Somewhat visible. AI bots can read Breast Cancer Recurrence, Early Stage 1, 2, Breast Cancer Test, India, but it is missing the structured signals that push citation rate above competitors.
AI engines read this profile 11 times
Meta AI · Claude · Apple Intelligence
#14,361 of 923,499 in Healthcare for AI visibility
7
AEO Visibility
iVisible · 6.5/10
40
Muse Index Score
iAI agent readiness
Agent-ready · 40/100
8
AI Adoption
iBasic · 8/100
About Breast Cancer Recurrence, Early Stage 1, 2, Breast Cancer Test, India
from our crawl and measurement
"OncoStem Diagnostics develops validated, accurate predictive tests like CanAssist Breast to guide personalized cancer treatment decisions." That is how Breast Cancer Recurrence, Early Stage 1, 2, Breast Cancer Test, India of Bengaluru introduces itself. To AI engines like ChatGPT and Perplexity it is partially visible, scoring 6.5 out of 10, readable in places and missing in others.
Our crawl found structured data on the page (WebPage, MedicalTest), a sitemap and a readable heading structure. It is missing an llms.txt file.
AI crawlers have visited once in our tracking, including ClaudeBot (Anthropic).
The 6 signals AI reads
Strong · Good · Fair · Weak
Structured Data
Weak
Organization / LocalBusiness JSON-LD that AI can read.
Content Structure
Strong
Clear headings and answer-style content.
Entity Clarity
Fair
How clearly your brand identity reads to AI.
E-E-A-T Signals
Experience, Expertise, Authority, Trust
Good
Experience, Expertise, Authority, Trust markers.
Technical AEO
Good
robots.txt, llms.txt, and AI-bot crawl access.
AI Discoverability
Strong
Sitemaps and entity links AI can follow.
Off-page authority
How the web signals your brand to AI
Backlinks
Strong
Inbound links from other sites.
Domain Authority
Weak
Little domain authority yet.
Reference Presence
Weak
Not in AI knowledge graphs yet.
News & Press
Weak
No press coverage found yet.
Community
Weak
No community discussion yet.
Social Mentions
Weak
No social discussion found yet.
What this score means
Your AEO score measures whether AI search engines - ChatGPT, Claude, Perplexity, Gemini - can actually read your site and cite it in answers. Roughly two-thirds of sites are invisible to them. At 6.5/10, Breast Cancer Recurrence, Early Stage 1, 2, Breast Cancer Test, India has a working base to build on - fixable, and the signals above are where to start.
Frequently Asked Questions
What is CanAssist Breast test ?
CanAssist Breast is a prognostic test that helps oncologists to determine the right treatment plan for each patient. The test classifies patients as 'low-risk' or 'high-risk' based on the patient's breast cancer recurrence risks over five years.
What is the core benefit of CanAssist Breast ?
CanAssist Breast helps to identify the likelihood of breast cancer returning post-surgery. Our test classifies patients as low-risk or high-risk based on the patient's breast cancer recurrence risks over five years. The clear-cut test result provides doctors with additional information that can be used for treatment planning.
When should CanAssist Breast be performed ?
The doctor needs to prescribe CanAssist Breast once surgery is completed, and before proceeding with the cancer treatment so that the treatment can be personalized for every patient.
How many days do you take to deliver CanAssist Breast report ?
CanAssist Breast report is available within eight business days from the date the FFPE block is received by OncoStem.
How can early-stage breast cancer patients potentially avoid chemotherapy ?
Each patient's cancer is unique. If you have been diagnosed with early-stage, invasive breast cancer, it is likely that you may not benefit from chemotherapy. Large scale studies have shown that many early-stage patients are over- treated. Once your risk of breast cancer recurrence is known, you can consult your doctor to personalize your treatment plan and possibly avoid the side effects of chemotherapy. Our Team
Is this your brand?
The exact fixes for Breast Cancer Recurrence, Early Stage 1, 2, Breast Cancer Test, India
Which AI engines already crawl you
Free AI bot monitoring: see every AI crawler that visits you
The AEO Checklist Every Small Business Owner Needs Right Now
Your potential customers are asking ChatGPT, Gemini, and Claude questions about your product category. These AI models are giving answers without sending traffic to your website. You're not losing rank. You're losing visibility entirely.
Continue reading in your free Engagemii portalFree signup unlocks the full article plus your personalized AEO fix list for Breast Cancer Recurrence, Early Stage 1, 2, Breast Cancer Test, India.
Source & Attribution
Scored by Engagemii on August 8, 2026. Methodology: engagemii.com/aeo/methodology
Source URL: https://engagemii.com/aeo/brands/oncostem
Cite this score: Engagemii (2026). "AEO Score for Breast Cancer Recurrence, Early Stage 1, 2, Breast Cancer Test, India." Retrieved from https://engagemii.com/aeo/brands/oncostem
Licensed under CC BY 4.0. You may reuse this data with attribution: a visible link to engagemii.com.
Powered by Engagemii - The Answer Engine Optimization (AEO) Platform